Senzime AB (publ)
SEZI
Rang in Aktien
#25403
Senzime AB (publ) is a medical technology firm specializing in the creation and... Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
Aktienkurs
$0.30213101
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$47.50M
Veränderung (1 Tag)
0.56%
Veränderung (1 Jahr)
-56.84%
Land
SE
Handel Senzime AB (publ) (SEZI)
Kategorie
Healthcare
Marktkapitalisierung von Senzime AB (publ)(SEZI)
Marktkapitalisierung: $47.50M
Mit Stand October 2026 hat Senzime AB (publ) eine Marktkapitalisierung von $47.50M. Das macht Senzime AB (publ) laut unseren Daten zum 25403rd wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von Senzime AB (publ) von 2017 bis 2026
SEZI im Vergleich zu den Top 5 der beliebtesten stocks
| Preis für SEZI | Vermögenswert B | Marktkapitalisierung von B | Ergebnisse | |
|---|---|---|---|---|
$32,866.07
$36.98M
|
$5.167T | +13,973,567.31% | ||
|
$31,897.58
$36.98M
|
$5.015T | +13,561,795.32% | ||
|
$26,132.37
$36.98M
|
$4.108T | +11,110,602.82% | ||
|
$24,818.90
$36.98M
|
$3.902T | +10,552,151.38% | ||
|
$17,106.86
$36.98M
|
$2.689T | +7,273,225.53% |
